RT Journal Article
SR Electronic
T1 The global burden of chikungunya virus and the potential benefit of vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.24.24315872
DO 10.1101/2024.10.24.24315872
A1 Ribeiro dos Santos, Gabriel
A1 Jawed, Fariha
A1 Mukandavire, Christinah
A1 Deol, Arminder
A1 Scarponi, Danny
A1 Mboera, Leonard E.G.
A1 Seruyange, Eric
A1 Poirier, Mathieu J.P.
A1 Bosomprah, Samuel
A1 Udeze, Augustine O.
A1 Dellagi, Koussay
A1 Hozé, Nathanael
A1 Chilongola, Jaffu
A1 Nasrallah, Gheyath K.
A1 Saathof, Elmar
A1 Cauchemez, Simon
A1 Salje, Henrik
YR 2024
UL http://medrxiv.org/content/early/2024/10/25/2024.10.24.24315872.abstract
AB The first chikungunya virus (CHIKV) vaccine has now been licensed, however, its potential to reduce disease burden remains unknown due to a poor knowledge of the underlying global burden. We use data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying burden in 190 countries and territories, and explore the potential impact of the vaccine. We estimate that 104 countries have experienced transmission, covering 2.8 billion individuals and that in epidemic settings, the mean duration between outbreaks is 6.2 years, with 8.4% of the susceptible population infected per outbreak. Globally there are 33.7 million annual infections, driven by countries in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% a protection against infection of 40%, vaccinating 50% of individuals over 12 years old in places and times where the virus circulates would avert 3,718 infections, 2.8 deaths and 158 DALYs per 100,000 doses used. These findings highlight the global burden and the significant potential of the vaccine.Competing Interest StatementGabriel Ribeiro dos Santos is a paid consultant by Valneva. Henrik Salje is a paid consultant by valneva.Funding StatementThis study was funded by CEPIAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All models were developed using anonymized datasets. The data was either extracted from existing publications or provided by the underlying data collectors without any personal identifiers. The datasets are credited to the local research groups that generated them.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe publicly available seroprevalence datasets will be made available on GitHub, along with the references of their article of origin where relevant. https://github.com/G-ribeiro-dos-santos/chik-global-burden